BG104779A - Inhibitors of phospholipase enzymes - Google Patents

Inhibitors of phospholipase enzymes

Info

Publication number
BG104779A
BG104779A BG104779A BG10477900A BG104779A BG 104779 A BG104779 A BG 104779A BG 104779 A BG104779 A BG 104779A BG 10477900 A BG10477900 A BG 10477900A BG 104779 A BG104779 A BG 104779A
Authority
BG
Bulgaria
Prior art keywords
inhibitors
phospholipase enzymes
compounds
mammal
administration
Prior art date
Application number
BG104779A
Other languages
Bulgarian (bg)
Inventor
Jasbir Seehra
John Mckew
Frank Lovering
Jean Bemis
Yibin Xiang
Lihren Chen
John Knopf
Original Assignee
Genetics Institute, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Institute, Llc filed Critical Genetics Institute, Llc
Publication of BG104779A publication Critical patent/BG104779A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Abstract

This invention concerns compounds and pharmaceutical compositions useful for treating and preventing inflammatory conditions in a mammal, the methods comprising administration of novel pharmaceutically useful compounds of general formulae or pharmaceutically acceptable salts thereof, wherein R1-R5 are as defined in the description. 33 claims
BG104779A 1998-02-25 2000-09-19 Inhibitors of phospholipase enzymes BG104779A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3059298A 1998-02-25 1998-02-25
PCT/US1999/003898 WO1999043654A2 (en) 1998-02-25 1999-02-24 Inhibitors of phospholipase enzymes

Publications (1)

Publication Number Publication Date
BG104779A true BG104779A (en) 2001-10-31

Family

ID=21854952

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104779A BG104779A (en) 1998-02-25 2000-09-19 Inhibitors of phospholipase enzymes

Country Status (21)

Country Link
EP (1) EP1062205A2 (en)
JP (1) JP2002504541A (en)
KR (1) KR20010041344A (en)
CN (1) CN1310706A (en)
AU (1) AU765427B2 (en)
BG (1) BG104779A (en)
BR (1) BR9908275A (en)
CA (1) CA2322162A1 (en)
EA (1) EA003876B1 (en)
EE (1) EE200000488A (en)
GE (1) GEP20032920B (en)
HR (1) HRP20000551A2 (en)
HU (1) HUP0101146A3 (en)
ID (1) ID26250A (en)
IL (1) IL137719A0 (en)
NO (1) NO20004219L (en)
NZ (1) NZ506329A (en)
PL (1) PL343007A1 (en)
SK (1) SK12752000A3 (en)
TR (1) TR200002447T2 (en)
WO (1) WO1999043654A2 (en)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19917504A1 (en) * 1999-04-17 2000-10-19 Dresden Arzneimittel New hydroxy-indole derivatives, useful in treatment of degenerative joint disease, viral and parasitic infections, bronchial, dermatological, neurodegenerative and prostate disorders, etc.
JP2002513783A (en) * 1998-05-01 2002-05-14 イーライ・リリー・アンド・カンパニー SPLA2 inhibitory compounds for treating diseases
TWI269654B (en) * 1999-09-28 2007-01-01 Baxter Healthcare Sa N-substituted indole-3-glyoxylamide compounds having anti-tumor action
DE19951360A1 (en) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituted indoles
DE19962300A1 (en) * 1999-12-23 2001-06-28 Asta Medica Ag New N-benzylindolyl glyoxylic acid derivatives are useful as antitumor agents
DE19963178A1 (en) * 1999-12-27 2001-07-05 Gruenenthal Gmbh Substituted indole Mannich bases
DE10006139A1 (en) * 2000-02-11 2001-08-16 Merck Patent Gmbh Indol-3-yl derivatives
AUPQ876400A0 (en) * 2000-07-14 2000-08-03 University Of Queensland, The Compositions and method of using them
AU7705601A (en) 2000-07-25 2002-02-05 Merck & Co Inc N-substituted indoles useful in the treatment of diabetes
DE10037310A1 (en) * 2000-07-28 2002-02-07 Asta Medica Ag New indole derivatives and their use as medicines
DE60126997T2 (en) 2000-10-20 2007-10-25 Eisai R&D Management Co., Ltd. NITROGEN-CONTAINING AROMATIC RING COMPOUNDS FOR THE TREATMENT OF TUMORARY DISEASES
CA2465534C (en) 2000-11-02 2009-10-27 Nigel H. Greig Agents useful for reducing amyloid precursor protein and treating dementia and methods of use thereof
DK1397130T3 (en) 2001-06-20 2007-11-12 Wyeth Corp Substituted Indole Acid Derivatives as Inhibitors of Plasminogen Activator Inhibitor-1 (PAI-1)
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
EP1844771A3 (en) * 2001-06-20 2007-11-07 Wyeth Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
JP2005500345A (en) 2001-08-03 2005-01-06 ファルマシア・アンド・アップジョン・カンパニー 5-Arylsulfonylindole with 5-HT6 receptor affinity
JP2005504790A (en) 2001-09-13 2005-02-17 シンタ ファーマスーティカルズ コーポレイション 3-glyoxylylamidoindole for treating cancer
US7605156B2 (en) 2001-12-03 2009-10-20 Wyeth Methods for the use of inhibitors of cytosolic phospholipase A2
US6984735B2 (en) 2001-12-03 2006-01-10 Wyeth Process for making an aldehyde
US6635771B2 (en) 2001-12-03 2003-10-21 Wyeth N-benzhydryl indole compounds
US7713964B2 (en) 2001-12-03 2010-05-11 Wyeth Llc Methods for treating asthmatic conditions
US7101875B2 (en) 2001-12-03 2006-09-05 Wyeth Methods for treating arthritic disorders
PL370445A1 (en) * 2001-12-03 2005-05-30 Wyeth Inhibitors of cytosolic phospholipase a2
US6797708B2 (en) 2001-12-03 2004-09-28 Wyeth Inhibitors of cytosolic phospholipase A2
AU2003224257A1 (en) * 2002-04-09 2003-10-27 Astex Technology Limited Heterocyclic compounds and their use as modulators of p38 map kinase
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
BR0313825A (en) 2002-08-29 2005-07-12 Merck & Co Inc Compound, pharmaceutical composition, method for treating type 2 diabetes mellitus in a mammal, and, compound use
AU2003260085B2 (en) 2002-08-29 2008-09-11 Merck & Co., Inc. Indoles having anti-diabetic activity
UA80453C2 (en) 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
DK1569900T3 (en) 2002-12-10 2006-10-23 Wyeth Corp Substituted 3-carbonyl-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
CA2509170A1 (en) 2002-12-10 2004-06-24 Wyeth Substituted 3-alkyl and 3-arylalkyl 1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
WO2004052854A2 (en) * 2002-12-10 2004-06-24 Wyeth Aryl, aryloxy, and alkyloxy substituted 1h-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
AU2003296323A1 (en) 2002-12-10 2004-06-30 Wyeth Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
US7129264B2 (en) * 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7342039B2 (en) 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7420083B2 (en) 2003-09-25 2008-09-02 Wyeth Substituted aryloximes
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
GB0412769D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
US7705023B2 (en) 2004-06-18 2010-04-27 Biolipox Ab Indoles useful in the treatment of inflammation
AU2005277138A1 (en) 2004-08-23 2006-03-02 Wyeth Holdings Corporation Oxazolo-naphthyl acids as plaminogen activator inhibtor type-1 (PAI-1) modulators useful in the treatment of thrombosis and cardiovascular diseases
KR20070053205A (en) 2004-09-17 2007-05-23 에자이 알앤드디 매니지먼트 가부시키가이샤 Medicinal composition
MX2007008759A (en) 2005-01-19 2007-09-11 Biolipox Ab Indoles useful in the treatment of inflammation.
WO2007024294A2 (en) 2005-05-03 2007-03-01 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
GT200600228A (en) 2005-05-27 2006-12-26 INHIBITORS OF PHOSPHOLIPASE A2 CITOSOLICA
WO2007015578A1 (en) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
BRPI0614340A2 (en) 2005-08-17 2011-04-12 Wyeth Corp replaced indoles and methods of use
GB0525141D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
US7645752B2 (en) 2006-01-13 2010-01-12 Wyeth Llc Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors
MY146494A (en) 2006-01-24 2012-08-15 Lilly Co Eli Indole sulfonamide modulators of progesterone receptors
WO2007092207A1 (en) * 2006-02-03 2007-08-16 Wyeth Compositions for the delivery of substituted naphthyl indole derivatives and methods of their use
RU2448708C3 (en) 2006-05-18 2017-09-28 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. ANTI-TUMOR MEANS AGAINST THYROID CANCER CANCER
EA018724B1 (en) 2006-08-07 2013-10-30 Айронвуд Фармасьютикалз, Инк. Indole compounds
WO2008026748A1 (en) 2006-08-28 2008-03-06 Eisai R & D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
MEP11809A (en) * 2006-10-19 2011-12-20 Indole compound
CN101600694A (en) 2007-01-29 2009-12-09 卫材R&D管理有限公司 Composition for treatment of undifferentiated-type of gastric cancer
JP5638244B2 (en) 2007-11-09 2014-12-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 Combination of angiogenesis inhibitors and antitumor platinum complexes
BRPI0906433A2 (en) 2008-01-31 2019-09-24 Sanofi Aventis cyclic indole-3-carboxamides, their preparation and their use as a pharmaceutical
KR101269393B1 (en) 2008-04-28 2013-05-29 아사히 가세이 파마 가부시키가이샤 Phenylpropionic acid derivative and use thereof
CA2802644C (en) 2010-06-25 2017-02-21 Eisai R & D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
AR084433A1 (en) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc FAAH INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CA2828946C (en) 2011-04-18 2016-06-21 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
WO2012166899A2 (en) 2011-06-03 2012-12-06 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
US8889730B2 (en) * 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
BR112015009004A8 (en) 2012-12-21 2021-07-20 Eisai R&D Man Co Ltd amorphous form of quinoline derivative and method of production thereof
CA2912219C (en) 2013-05-14 2021-11-16 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
KR20230043234A (en) 2014-08-28 2023-03-30 에자이 알앤드디 매니지먼트 가부시키가이샤 High-purity quinoline derivative and method for manufacturing same
AU2016224583B2 (en) 2015-02-25 2021-06-03 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
KR20170122809A (en) 2015-03-04 2017-11-06 머크 샤프 앤드 돔 코포레이션 A combination of a PD-1 antagonist and a VEGFR / FGFR / RET tyrosine kinase inhibitor to treat cancer
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
WO2017073060A1 (en) * 2015-10-29 2017-05-04 国立大学法人東北大学 Collagen production inhibitor
CN106810488B (en) * 2015-11-27 2021-02-19 中国科学院上海药物研究所 One class is used as GPR17 and CysLT1Compound of dual antagonist, preparation method and application thereof
CN108530354B (en) * 2018-05-07 2019-12-10 青岛农业大学 Synthesis method of benzenesulfonyl quinoline compound
MX2021003904A (en) 2018-10-05 2021-10-26 Annapurna Bio Inc Compounds and compositions for treating conditions associated with apj receptor activity.

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3271416A (en) * 1961-10-24 1966-09-06 Merck & Co Inc Indolyl aliphatic acids
GB1148909A (en) * 1965-04-19 1969-04-16 Sumitomo Chemical Co Process for production of novel phenylhydrazone and phenylhydrazine derivatives
SE314373B (en) * 1966-04-12 1969-09-08 Sumitomo Chemical Co
FR1583552A (en) * 1967-04-11 1969-11-14
FR2152377A1 (en) * 1971-09-09 1973-04-27 Sumitomo Chemical Co 1-phenyl-2-methyl-5-alkyl or alkoxy-3-indolylacetic acid - derivs - antiinflammatory, analgesic, antipyretic
BE790679A (en) * 1971-11-03 1973-04-27 Ici Ltd INDOLE DERIVATIVES
US4894386A (en) * 1987-04-15 1990-01-16 Ici Americas Inc. Aliphatic carboxamides
CA1337202C (en) * 1988-04-13 1995-10-03 Victor Giulio Matassa Cyclic amides which are leukotriene antagonists
GB8906032D0 (en) * 1988-04-14 1989-04-26 Ici America Inc Hetera-aliphatic carboxamides
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
US5095031A (en) * 1990-08-20 1992-03-10 Abbott Laboratories Indole derivatives which inhibit leukotriene biosynthesis
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
DE4338770A1 (en) * 1993-11-12 1995-05-18 Matthias Dr Lehr Indole-2-alkanoic acids and their derivatives as inhibitors of phospholipase A¶2¶
ES2377223T3 (en) * 1994-04-01 2012-03-23 Eli Lilly And Company [[3- (2-Amino-1,2-dioxoethyl) -2-ethyl-1- (phenylmethyl) -11H-indole-4-IL] oxy] acetic acid methyl ester as an inhibitor of sPLA2
US5604253A (en) * 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5639780A (en) * 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
EP0863873B1 (en) * 1995-10-10 1999-11-10 Pfizer Inc. Indole carbamates as leukotriene antagonists
KR100482268B1 (en) * 1996-08-01 2005-04-14 메르클레 게엠베하 Acylpyrroldicarboxylic acids and acylindoldicarboxylic acids and their derivatives and inhibitors of the cytosolic phospholipase a2
WO1998008818A1 (en) * 1996-08-26 1998-03-05 Genetics Institute, Inc. Inhibitors of phospholipase enzymes

Also Published As

Publication number Publication date
EE200000488A (en) 2002-02-15
TR200002447T2 (en) 2000-11-21
IL137719A0 (en) 2001-10-31
EA003876B1 (en) 2003-10-30
EA200000871A1 (en) 2001-04-23
HUP0101146A3 (en) 2001-11-28
AU2782599A (en) 1999-09-15
SK12752000A3 (en) 2001-03-12
HRP20000551A2 (en) 2001-04-30
WO1999043654A3 (en) 1999-10-28
WO1999043654A2 (en) 1999-09-02
ID26250A (en) 2000-12-07
CA2322162A1 (en) 1999-09-02
KR20010041344A (en) 2001-05-15
NO20004219L (en) 2000-10-23
BR9908275A (en) 2000-10-24
AU765427B2 (en) 2003-09-18
PL343007A1 (en) 2001-07-30
NZ506329A (en) 2004-01-30
HUP0101146A2 (en) 2001-08-28
JP2002504541A (en) 2002-02-12
NO20004219D0 (en) 2000-08-23
EP1062205A2 (en) 2000-12-27
GEP20032920B (en) 2003-03-25
CN1310706A (en) 2001-08-29

Similar Documents

Publication Publication Date Title
BG104779A (en) Inhibitors of phospholipase enzymes
BG106586A (en) Pyrazolopyramidines as therapeutic agents
BG106075A (en) Use of cyp2d6 inhibitors in combination therapies
AU3664401A (en) Platelet adp receptor inhibitors
WO1999005096A3 (en) Urokinase inhibitors
BG104780A (en) Inhibitors of phospholipase enzymes
BG106020A (en) Inhibitors of impdh enzyme
MY133996A (en) Compounds for the treatment of ischemia
NO20003018D0 (en) Triazinangiogenese inhibitors
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
BG103995A (en) Reverse hydroxamate inhibitors of matrix metalloprreverse hydroxamate inhibitors of matrix metallprooteinases teinases
SI1509232T1 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
IL129592A0 (en) 5-HT1f agonists
CR6682A (en) NON-PEPTIDIC INHIBITORS OF THE VLA-4 DEPENDENT CELL UNION IN THE TREATMENT OF INFLAMMATORY, AUTOIMMUNE AND RESPIRATORY DISEASES
PT915898E (en) CLARITROMYCIN CRYSTALLINE I FORM
ZA200108082B (en) Pharmaceutical compositions comprising dipeptidy peptidase IV inhibitors for the promotion of growth.
BG105270A (en) Tetrahydropyridoethers
GEP20043383B (en) Cell Adhesion-Inhibiting Antiinflammatory and Immune-Suppressive Compounds
YU87202A (en) Arylmethylamine derivatives for use as tryptase inhibitors
IL124883A0 (en) Amidino protease inhibitors and pharmaceutical compositions containing the same
NZ331484A (en) Serine protease inhibitors having an alkynylamino side chain for use in treatment of thrombin related diseases
WO2001091738A3 (en) Naaladase inhibitors for treating amyotrophic lateral sclerosis
ATE297904T1 (en) HALO-ALKOXYCARBONYL COMPOUNDS
WO1999012933A3 (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase
MX9605196A (en) HALOMETHYL AMIDES AS IL-1'beta' PROTEASE INHIBITORS.